Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.55 USD | -0.18% | +0.18% | +8.55% |
05-16 | Axonics Implant Approved in Australia to Treat Overactive Bladders | MT |
04-30 | Axonics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.55% | 3.45B | |
+11.76% | 127B | |
-5.10% | 11.32B | |
+4.02% | 9.04B | |
+38.12% | 5.56B | |
-23.70% | 4.72B | |
-6.44% | 2.86B | |
-5.85% | 2.07B | |
-11.84% | 2.04B | |
-23.36% | 1.77B |
- Stock Market
- Equities
- AXNX Stock
- News Axonics, Inc.
- Morgan Stanley Adjusts Price Target on Axonics to $76 From $92, Maintains Overweight Rating